[New screening method for coagulation abnormality including AT III deficiency during CABG]

Area of Science:

• Cardiovascular Surgery
• Hematology
• Anesthesiology

Context:

• Patients undergoing Coronary Artery Bypass Grafting (CABG) often receive heparin to prevent thrombosis.
• Coagulation abnormalities, such as Antithrombin III (AT III) deficiency, can complicate CABG procedures.
• Standard heparin protocols may not adequately identify all patients at risk for bleeding or clotting complications.

Purpose:

• To evaluate the utility of Activated Clotting Time (ACT) testing as a screening tool for coagulation abnormalities.
• To determine if ACT measurement before and after a standard heparin dose can identify patients with AT III deficiency.
• To establish a simple, convenient method for assessing coagulation status during CABG.

Summary:

• A study involving 100 patients undergoing CABG assessed ACT before (c-ACT) and after (h-ACT) 1 ml heparin administration.
• ACT extension (c-ACT - h-ACT) was calculated; a value less than 30 seconds indicated potential issues.
• Two of three patients with ACT extension < 30 seconds had AT III deficiency, suggesting ACT's screening capability.

Impact:

• This study introduces a novel, straightforward screening method for identifying coagulation disorders during CABG.
• Early detection of abnormalities like AT III deficiency can lead to timely interventions, potentially improving patient outcomes.
• The ACT test provides a practical approach to enhance patient safety in cardiac surgery settings.